Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis, and ulcerative colitis.[7][8][9] It is a janus kinase (JAK) inhibitor,[7][8] discovered and developed by the National Institutes of Health and Pfizer.
Common side effects include diarrhea, headache, and high blood pressure.[9] Serious side effects may include infections, cancer, and pulmonary embolism.[9][10] In 2019, the safety committee of the European Medicines Agency began a review of tofacitinib and recommended that doctors temporarily not prescribe the 10 mg twice-daily dose to people at high risk for pulmonary embolism.[11] The U.S. Food and Drug Administration (FDA) also released warnings about the risk of blood clots.[12][13][14] An important side effect of Jakinibs is serious bacterial, mycobacterial, fungal and viral infections. In the phase III trials of tofacitinib among opportunistic infections, pulmonary tuberculosis (TB) was reported in 3 cases all of which were initially negative upon screening for TB.[15]
It was approved for medical use in the United States in November 2012.[16] The extended release version was approved in February 2016.[17] It is available as a generic medication.[18]
^"Tofacitinib Use During Pregnancy". Drugs.com. 15 April 2020. Retrieved 23 October 2020.
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^"Xeljanz/Xeljanz XR (Pfizer Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Retrieved 10 April 2023.
^"Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^"10 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 13 October 2020. Retrieved 3 November 2020.
^"Xeljanz 11 mg prolonged release tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 3 November 2020.
^ abcCite error: The named reference Xeljanz FDA label was invoked but never defined (see the help page).
^ abc"Tofacitinib Citrate". The American Society of Health-System Pharmacists. Retrieved 1 June 2018.
^"Safety Alerts for Human Medical Products - Xeljanz, Xeljanz XR (tofacitinib): Safety Communication - Safety Trial Finds Increased Risk of Blood Clots in the Lungs and Death with Higher Dose in Rheumatoid Arthritis Patients". U.S. Food and Drug Administration (FDA). Retrieved 2 March 2019. This article incorporates text from this source, which is in the public domain.
^"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2019, May 17, 2019". European Medicines Agency. 17 May 2019. Retrieved 17 May 2019.
^"Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication - Due to an Increased Risk of Blood Clots and Death with Higher Dose". U.S. Food and Drug Administration (FDA). 26 July 2019. Archived from the original on 15 December 2019. Retrieved 10 August 2019. This article incorporates text from this source, which is in the public domain.
^FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). U.S. Food and Drug Administration (FDA) (Podcast). 5 August 2019. Retrieved 15 December 2019.
^"FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)". U.S. Food and Drug Administration. 15 December 2019. Archived from the original on 15 December 2019. Retrieved 15 December 2019.
^O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A (April 2013). "Janus kinase inhibitors in autoimmune diseases". Annals of the Rheumatic Diseases. 72 (Suppl 2): ii111–ii115. doi:10.1136/annrheumdis-2012-202576. PMC 3616338. PMID 23532440.
^"Drug Approval Package: Xeljanz (tofacitinib) Tablets NDA #203214". U.S. Food and Drug Administration (FDA). 28 December 2012. Retrieved 30 June 2023.
^"Drug Approval Package: Xeljanz (tofacitinib) Extended Release (XR) Tablets NDA #208246". U.S. Food and Drug Administration (FDA). 26 June 2017. Retrieved 30 June 2023.
^"First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis...
The US Food and Drug Administration (FDA) requires a boxed warning for tofacitinib, baricitinib, and upadacitinib to include information about the risks...
been explored, including immunomodulatory agents such as imiquimod. Tofacitinib citrate may also have benefits. In June 2014, a 25-year-old man with...
gene expression in immunological cells. Other JAK inhibitors include tofacitinib, which is indicated for the treatment of rheumatoid arthritis, psoriatic...
colitis, myeloid metaplasia with myelofibrosis and vitiligo. Examples are tofacitinib, baricitinib, upadacitinib and filgotinib. In 2014 researchers discovered...
current generic equivalent available on the market. The JAK1 inhibitors tofacitinib (Xeljanz) and upadacitinib (Rinvoq) are approved for the use in active...
The US Food and Drug Administration (FDA) requires a boxed warning for tofacitinib, baricitinib, and upadacitinib to include information about the risks...
surgery, hospitalization, pregnancy, the use of corticosteroids and tofacitinib, a JAK inhibitor. Osteoporosis may occur related to systemic inflammation...
vitiligo and other skin diseases. A medication for rheumatoid arthritis, tofacitinib, has been tested for the treatment of vitiligo. In October 1992, a scientific...
combination with either methotrexate or leflunomide. Biologic monotherapy or tofacitinib with methotrexate may improve ACR50, RA remission rates and function...
availability of TNF inhibitors and other agents, such as tocilizumab and tofacitinib. Penicillamine works by reducing numbers of T-lymphocytes, inhibiting...
received approval from the Food and Drug Administration for Xeljanz, a tofacitinib, for rheumatoid arthritis and ulcerative colitis. The drug had sales...
rheumatoid arthritis was tofacitinib. It has also shown promising results in other autoimmune disorders. Initially, tofacitinib was thought to be a selective...
Global Information
This article incorporates text from this source, which is in the public domain.
